Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
33.78
+2.79 (9.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
Zai Lab Revenue
Zai Lab had revenue of $102.27M in the quarter ending September 30, 2024, with 47.72% growth. This brings the company's revenue in the last twelve months to $355.75M, up 35.01% year-over-year. In the year 2023, Zai Lab had annual revenue of $266.72M with 24.03% growth.
Revenue (ttm)
$355.75M
Revenue Growth
+35.01%
P/S Ratio
9.26
Revenue / Employee
$163,562
Employees
2,175
Market Cap
3.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
| Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ZLAB News
- 25 days ago - Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025 - Business Wire
- 4 weeks ago - Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC) - Business Wire
- 5 weeks ago - Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia - Business Wire
- 5 weeks ago - Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
- 6 weeks ago - Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore - Business Wire
- 6 weeks ago - Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore - Business Wire
- 6 weeks ago - Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate - Business Wire
- 2 months ago - Zai Lab: Rapidly Improving Outlook Bodes Well For The Future - Seeking Alpha